A Randomized Phase 1 Pharmacokinetic Study Comparing the Potential Biosimilar LRG201902 With Liraglutide (Victoza(®)) in Healthy Male Subjects

Objective: Pharmacokinetic (PK) similarity between biosimilar candidate LRG201902 and European Union-sourced liraglutide reference product (Victoza(®)) was evaluated. Safety and immunogenicity were also assessed. Methods: This single-dose, randomized, open-label, 2-period crossover study (CTR2019234...

Descripción completa

Detalles Bibliográficos
Autores principales: Mai, Gang, Fan, Lianlian, Li, Mupeng, Zhang, Peiwen, Gan, Chunyan, Huang, Qian, Shentu, Jianzhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7878668/
https://www.ncbi.nlm.nih.gov/pubmed/33584289
http://dx.doi.org/10.3389/fphar.2020.610880

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7878668/
https://www.ncbi.nlm.nih.gov/pubmed/33584289
http://dx.doi.org/10.3389/fphar.2020.610880

Ejemplares similares